公开(公告)号：US11655289B2

公开(公告)日：2023-05-23

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: A61K39/395 ,  C07K16/18 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/94

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.

公开(公告)号：US20210363259A1

公开(公告)日：2021-11-25

申请号：US16640422

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Tia Brie Estey ,  Geetha Govindan ,  Sonal Saluja ,  Kapil Gupta ,  Margaret McGrath

IPC: C07K16/28 ,  A61K47/18 ,  A61K47/26 ,  A61K31/4418 ,  A61K31/496 ,  A61K47/12 ,  A61K47/20

Abstract: Formulations and dosage regimens of an anti-αvβ6 antibody or αvβ6-binding fragment thereof are provided. These formulations find use in the treatment of e.g., fibrosis (e.g., idiopathic pulmonary fibrosis), acute lung injury, and acute kidney injury.

公开(公告)号：US20240043513A1

公开(公告)日：2024-02-08

申请号：US18300339

申请日：2023-04-13

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K2039/505

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or Aβ-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and Aβ-associated disorders such as Alzheimer's disease.

公开(公告)号：US20190064147A1

公开(公告)日：2019-02-28

申请号：US15544315

申请日：2016-01-18

Applicant: Biogen MA Inc.

Inventor： Mark Krebs ,  Mariana Dimitrova ,  Kapil Gupta ,  Shantanu Sule ,  Randall Mauldin ,  Adnan Zunic ,  Lori Karpes

IPC: G01N33/50 ,  A61K47/12 ,  G01N33/68 ,  A61K47/18 ,  A61K47/26 ,  G01N33/84 ,  G01N33/94 ,  C07K1/113 ,  G01N33/15

Abstract: Provided herein, in some aspects, are methods of developing a biological therapeutic product. The methods can be used to formulate a biological therapeutic agent or screen biological therapeutic agents.

公开(公告)号：US20210188954A1

公开(公告)日：2021-06-24

申请号：US16639338

申请日：2018-08-22

Applicant: Biogen MA Inc.

Inventor： Steven Andrew Lantz ,  Kapil Gupta ,  Shantanu Sule ,  Adnan Zunic

IPC: C07K16/18 ,  A61K39/395 ,  A61K47/18 ,  A61K47/26 ,  A61K47/22 ,  A61K47/20

Abstract: Pharmaceutical compositions containing anti-beta amyloid (Aβ) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of Aβ in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.